MRKR
Income statement / Annual
Last year (2023), Marker Therapeutics, Inc.'s total revenue was $3.31 M,
a decrease of 63.23% from the previous year.
In 2023, Marker Therapeutics, Inc.'s net income was -$14.05 M.
See Marker Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$3.31 M
|
$9.00 M
|
$1.24 M
|
$466,785.00
|
$213,194.00
|
$205,994.00
|
$183,064.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$10.42 M |
$3.68 M |
$3.16 M |
$18.88 M |
$12.76 M |
$124.00 M |
$5.25 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$7.11 M |
$5.32 M |
-$1.92 M |
-$18.41 M |
-$12.55 M |
-$123.79 M |
-$5.07 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
-2.15 |
0.59 |
-1.55 |
-39.45 |
-58.87 |
-600.95 |
-27.68 |
0 |
0 |
0 |
| Research and Development
Expenses |
$10.42 M
|
$26.14 M
|
$27.79 M
|
$18.88 M
|
$12.76 M
|
$124.00 M
|
$5.25 M
|
$3.80 M
|
$1.71 M
|
$189,000.00
|
| General & Administrative
Expenses |
$7.48 M
|
$12.82 M
|
$12.92 M
|
$10.47 M
|
$9.98 M
|
$24.38 M
|
$6.41 M
|
$4.69 M
|
$4.45 M
|
$3.18 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.48 M
|
$12.82 M
|
$12.92 M
|
$10.47 M
|
$9.98 M
|
$24.38 M
|
$6.41 M
|
$4.69 M
|
$4.45 M
|
$3.18 M
|
| Other Expenses |
$0.00 |
-$232,974.00 |
-$2.41 M |
$0.00 |
$0.00 |
$116.05 M |
-$183,064.00 |
$1,828.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$17.89 M |
$38.96 M |
$40.72 M |
$29.35 M |
$22.74 M |
$148.38 M |
$11.48 M |
$8.26 M |
$6.16 M |
$3.37 M |
| Cost And Expenses |
$17.89 M |
$38.96 M |
$40.72 M |
$29.35 M |
$22.74 M |
$148.38 M |
$11.48 M |
$8.26 M |
$6.16 M |
$3.37 M |
| Interest Income |
$539,158.00 |
$248,063.00 |
$5,700.00 |
$148,742.00 |
$1.08 M |
$253,723.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$10,925.00 |
$575,543.00 |
| Depreciation &
Amortization |
$2.79 M
|
$3.68 M
|
$3.16 M
|
$1.08 M
|
$286,582.00
|
$148.17 M
|
$11.48 M
|
$8.49 M
|
-$27.90 M
|
-$26.94 M
|
| EBITDA |
-$11.79 M
|
-$19.79 M
|
-$36.32 M
|
-$27.63 M
|
-$22.03 M
|
-$147.97 M
|
-$11.30 M
|
$6.04 M
|
-$34.06 M
|
-$30.31 M
|
| EBITDA Ratio |
-3.56 |
-2.92 |
-29.25 |
-59.64 |
-104.41 |
-719.11 |
-65.43 |
0 |
0 |
0 |
| Operating Income Ratio
|
-4.4
|
-3.33
|
-31.79
|
-61.88
|
-105.67
|
-719.3
|
-63.71
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$539,158.00
|
$15,089.00
|
-$2.40 M
|
$179,742.00
|
$1.10 M
|
$213,723.00
|
$497,865.00
|
$6.04 M
|
-$27.91 M
|
-$27.51 M
|
| Income Before Tax |
-$14.04 M |
-$29.93 M |
-$41.88 M |
-$28.71 M |
-$21.43 M |
-$147.96 M |
-$10.98 M |
-$2.46 M |
-$34.07 M |
-$30.88 M |
| Income Before Tax Ratio
|
-4.24
|
-3.32
|
-33.73
|
-61.5
|
-100.51
|
-718.26
|
-59.99
|
0
|
0
|
0
|
| Income Tax Expense |
$3,675.00 |
-$15,089.00 |
-$5,700.00 |
-$179,742.00 |
-$1.10 M |
-$213,723.00 |
-$680,929.00 |
-$6.04 M |
$27.90 M |
$26.94 M |
| Net Income |
-$14.05 M |
-$29.92 M |
-$41.87 M |
-$28.53 M |
-$20.33 M |
-$147.96 M |
-$10.98 M |
-$2.46 M |
-$34.07 M |
-$30.88 M |
| Net Income Ratio |
-4.24 |
-3.32 |
-33.72 |
-61.11 |
-95.35 |
-718.26 |
-59.99 |
0 |
0 |
0 |
| EPS |
-1.93 |
-3.58 |
-5.47 |
-6.06 |
-4.46 |
-77.5 |
-11.62 |
-3.56 |
-93.02 |
-239.63 |
| EPS Diluted |
-1.93 |
-3.58 |
-5.47 |
-6.06 |
-4.46 |
-77.5 |
-11.62 |
-3.31 |
-93.02 |
-239.63 |
| Weighted Average Shares
Out |
$8.81 M
|
$8.35 M
|
$7.65 M
|
$4.70 M
|
$4.56 M
|
$1.91 M
|
$945,348.00
|
$688,989.00
|
$366,225.00
|
$128,876.00
|
| Weighted Average Shares
Out Diluted |
$8.81 M
|
$8.35 M
|
$7.65 M
|
$4.70 M
|
$4.56 M
|
$1.91 M
|
$945,348.00
|
$742,099.00
|
$366,225.00
|
$128,876.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
